alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with morphine in 1 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (morphine) | Trials (morphine) | Recent Studies (post-2010) (morphine) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 44,270 | 5,200 | 8,695 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | morphine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.2939 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.2278 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.0828 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0385 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0545 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.122 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1199 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.9308 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.655 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.3305 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.202 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, FS; Kitanaka, J; Kitanaka, N; Nishiyama, N; Takemura, M; Tanaka, K; Uhl, GR | 1 |
1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and morphine
| Article | Year |
|---|---|
Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Male; Methamphetamine; Mice; Mice, Inbred Strains; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Phenazocine; Pyrimidines; Receptors, Opioid, delta; Reflex; Tail; Time Factors | 2012 |